Research progress of B7-H3 in malignant tumors
B7 homolog 3 (B7-H3, also known as CD276) is a novel member of the B7 immune protein family. There is a marked difference in the expression and distribution of B7-H3 protein and mRNA between normal and tumor tissues, with widespread expression in tumor tissues and a close relationship with tumor pro...
Saved in:
| Main Authors: | Shuaixiang Zhao, He Zhang, Guanning Shang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586759/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Research progress of B7-H3 in malignant tumors
by: Shuaixiang Zhao, et al.
Published: (2025-06-01) -
B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature
by: Sylwia Mielcarska, et al.
Published: (2025-08-01) -
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications
by: Guo Y, et al.
Published: (2025-03-01) -
B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature
by: Sylwia Mielcarska, et al.
Published: (2025-04-01) -
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
by: Qi Shen, et al.
Published: (2024-12-01)